FIELD: biotechnology.
SUBSTANCE: invention relates to biotechnology, namely to method of producing activated cytotoxic lymphocytes, and can be used in medicine. Peripheral mononuclears are recovered from blood of oncological patients or donors and then they are cultured in serum-free medium ex vivo with addition of recombinant human IL-2 in concentration from 125 ng/ml to 500 ng/ml and IL-15 in concentration from 2.5 ng/ml to 5 ng/ml.
EFFECT: obtained cytotoxic lymphocytes with high output have high viability, proliferative activity and functional anticancer activity.
3 cl, 8 dwg, 6 ex
| Title | Year | Author | Number |
|---|---|---|---|
| METHOD OF PRODUCING CYTOTOXIC LYMPHOCYTES USING IFN-γ AND TNF-α FOR ADOPTIVE IMMUNOTHERAPY | 2023 |
|
RU2822876C2 |
| METHOD FOR LONG-TERM CULTIVATION AND EXPANSION OF NK CELLS WITH HIGH VIABILITY AND FUNCTIONAL ACTIVITY | 2021 |
|
RU2794770C1 |
| METHOD OF TREATING ONCOLOGICAL PATIENTS WITH CYTOTOXIC LYMPHOCYTES | 2015 |
|
RU2596505C1 |
| METHOD FOR EXPANSION OF HUMAN NK CELLS USING FEEDER CELLS | 2021 |
|
RU2781777C2 |
| METHOD OF TREATMENT OF PATIENTS WITH HERPES VIRUS INFECTION USING IN VITRO ACTIVATED AUTOLOGICAL LYMPHOCYTES | 2022 |
|
RU2799141C2 |
| METHOD FOR PRODUCTION OF IN VITRO POPULATIONS OF ACTIVATED ANTIGENSPECIFIC ANTITUMOR-TUMOR CYTOTOXIC T-LYMPHOCYTES SPECIFIC TO TUMOR-ASSOCIATED ANTIGEN EPITOPES | 2016 |
|
RU2619186C1 |
| METHOD FOR GENERATION OF SPECIFIC IMMUNE RESPONSE ON HUMAN IMMUNODEFICIENCY VIRUS ANTIGENS | 2011 |
|
RU2465324C1 |
| RECOMBINANT CELL LINE TMDK562-15 SHOWING THE ABILITY TO ACTIVATE AND PROLIFERATE HUMAN NK CELLS | 2022 |
|
RU2803178C1 |
| METHOD FOR OBTAINING OF MATURE ANTIGEN-ACTIVATED DENDRITIC CELLS WITH TRANSFECTION OF TUMOUR CELLS RNA OF BREAST CANCER | 2016 |
|
RU2631792C2 |
| IMMUNOTHERAPY OF BREAST CANCER USING ANTIGEN-ACTIVATED DENDRITIC CELLS | 2016 |
|
RU2645464C1 |
